The global longevity and anti-senescence therapy market was valued at $25.1 billion in 2020 and is expected to reach $44.2 billion by 2030, registering a CAGR of 6.1% from 2021 to 2030. The market is driven by an aging global population, rising prevalence of age-related diseases, and rapid advancements in senolytic drug therapy, gene therapy, and immunotherapy. Anti-senescence therapies target the biological mechanisms of cellular aging, offering transformative potential in oncology, metabolic disorders, and chronic disease management. Hospitals and medical service institutions are the primary end users, accelerating clinical adoption of next-generation longevity treatments worldwide:
Market Snapshot:
- Market Value (2020): $25.1 Billion
- Forecast (2030): $44.2 Billion
- CAGR: 6.1%
- Forecast Period: 2021–2030
- Market Driver: Aging global population and rising age-related chronic disease burden
- Key Therapies: Senolytic drug therapy, gene therapy, immunotherapy
- Top Application: Cancer treatment leads; other age-related conditions expanding rapidly
- End Users: Hospitals and specialized medical service institutions
- Key Trends: Growing R&D investment in cellular reprogramming and senolytics pipelines
- Regional Highlights: North America dominates; Asia-Pacific emerging as high-growth market due to aging demographics
Access Sample Data & Findings:
https://www.alliedmarketresearch.com/request-sample/14379
Leading Market Players –
- AgeX Therapeutics, Inc.
- Bristol-Myers Squibb Company
- Calico Life Sciences LLC
- CohBar, Inc.
- Life Biosciences, Inc.
- Merck & Co., Inc.
- Oisin Biotechnologies
- Pfizer Inc.
- T.A. Sciences, Inc.
- Unity Biotechnology, Inc.
Drivers, Restraints, and Opportunities:
Rise in prevalence of chronic diseases, surge in awareness about anti-aging products, and advancements in AI-driven medical technology drive the growth of the global longevity and anti-senescence therapy market. However, dearth of skilled professionals and loss of tissue-repair capacity restrain the market growth. On the other hand, surge in demand for cell-based assays in R&D activities presents new opportunities in the coming years.
The disease is caused by a virus, namely, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted among humans. Amidst the initial outbreak of COVID-19, number of patients to undergo implant surgery declined, owing to the fear of infection during pandemic. Moreover, the demand for the antiaging treatment products was reduced. The production plants of the antiaging products were shut down during the lockdown imposed by the governments across the globe. In addition, lockdown created a financial crisis among the market players.
This led to disturbances in import and export of anti-aging products across the countries. It was slightly positive amid the COVID-19 pandemic with an increase observed in prevalence of cardiovascular diseases, neural degenerative diseases, ophthalmology disorders, and cancer. For instance, according to data by the American Heart Association, in 2020, average person in the U.S. has a stroke every 40 seconds, accounting for one out of every 19 deaths. Overall, COVID-19 negatively impacted the longevity and anti-senescence therapy market. This was attributed to decrease in demand for anti-aging treatment products. Moreover, market players reduced investment in raw materials and resources, owing to decrease in number of hospital admissions of patients to undergo antiaging treatment.
★ See What’s Inside This Report @
https://www.alliedmarketresearch.com/purchase-enquiry/14379
The hospital segment to maintain its leadership status throughout the forecast period
Based on end user, the hospital segment accounted for the highest market share in 2020, contributing to more than half of the global longevity and anti-senescence therapy market, and is estimated to maintain its leadership status throughout the forecast period. This is attributed to rise in prevalence of chronic diseases in both developed and developing countries and rise in demand for longevity and anti-senescence therapy. However, the medical service institution segment is expected to manifest the highest CAGR of 6.5% from 2021 to 2030, owing to increase in government initiatives and rise in the adoption of anti-aging products.
North America to maintain its dominance in terms of revenue by 2030
Based on region, North America held the highest market share in terms of revenue in 2020, accounting for more than one-third of the global longevity and anti-senescence therapy market, and is projected to maintain its dominance in terms of revenue by 2030. This is due to surge in demand for anti-aging products, availability of advanced healthcare facilities with trained medical professionals, and presence of key market players. However, Asia-Pacific is projected to portray the fastest CAGR of 6.9% during the forecast period, owing to rise in demand for anti-aging products and availability of advanced healthcare facilities with trained medical professionals.
KEY FINDINGS OF THE STUDY –
♦ Depending on therapy, the gene therapy segment held majority share in the global longevity and anti-senescence therapy market forecast in 2020.
♦ Depending on application, the cancer segment held majority share in the global market in 2020.
♦ According to end user, the hospitals segment held majority share in the global market in 2020.
♦ Region wise, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 6.9% during the forecast period.
The global longevity and anti-senescence therapy market size is segmented on the basis of therapy, application, end user and region. Depending on therapy, it is categorized into senolytic drug therapy, gene therapy and immunotherapy. On the basis of application, the market is classified as cancer and others. According to end user, it is classified into hospitals and medical service institution. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
About Us
Allied Market Research (AMR) is a full-service market research and business consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides end-to-end solutions along with information, education, advocacy, and networking resources to SMEs and early-stage start-ups to bring excellence to their processes. In addition, we offer a nurturing environment required to develop and grow businesses, including business planning; virtual support; market intelligence; acquiring resources; and getting direct access to finance, suppliers, and other experts to boost the growth of businesses and entrepreneurs.
Our bundled and hassle-free business support systems are customized to meet the needs of SME consultants and industry leaders. Moreover, our large network of skilled consultants and experts help start-ups get the business on a roll.
Contact:
David Correa
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Toll Free: +1-800-792-5285
Int’l: +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
[email protected]
